We are live on ! Find out more
BB

BB Biotech Portfolio holdings

AUM $3.98B
1-Year Est. Return 15.47%
This Fund
S&P 500
This Quarter Est. Return
+31.67%
1 Year Est. Return
+15.47%
3 Year Est. Return
+121.5%
5 Year Est. Return
+265.65%
10 Year Est. Return
–
AUM
$3.09B
AUM Growth
+$628M
Cap. Flow
+$36.4M
Cap. Flow %
1.18%
Top 10 Hldgs %
71.33%
Holding
29
New
3
Increased
10
Reduced
10
Closed
1

Top Buys

Rank Stock Value
1
PTCT icon
PTC Therapeutics
PTCT
+$54.1M
2
TTPH
Tetraphase Pharmaceuticals, Inc.
TTPH
+$35M
3
GILD icon
Gilead Sciences
GILD
+$15.5M
4
CEMP
Cempra, Inc.
CEMP
+$11.6M
5
PBYI icon
Puma Biotechnology
PBYI
+$9.98M

Top Sells

Rank Stock Value
1
IONS icon
Ionis Pharmaceuticals
IONS
+$32.6M
2
CELG
Celgene Corp
CELG
+$18.5M
3
INCY icon
Incyte
INCY
+$16.3M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$13.8M
5
ALXN
Alexion Pharmaceuticals
ALXN
+$10.2M

Sector Composition

Rank Sector Weight
1 Healthcare 81.51%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CELG
1
DELISTED
Celgene Corp
CELG
$415M 13.46%
3,714,298
-175,000
-4% -$18.5M
IONS icon
2
Ionis Pharmaceuticals
IONS
$9.4B
$369M 11.95%
5,976,526
-660,000
-10% -$32.6M
INCY icon
3
Incyte
INCY
$24.4B
$296M 9.59%
4,051,867
-250,000
-6% -$16.3M
GILD icon
4
Gilead Sciences
GILD
$165B
$278M 8.99%
2,945,596
+150,000
+5% +$15.5M
AGIO icon
5
Agios Pharmaceuticals
AGIO
$1.93B
$209M 6.77%
1,864,921
-25,600
-1% -$2.29M
VRTX icon
6
Vertex Pharmaceuticals
VRTX
$126B
$161M 5.21%
1,354,445
– –
MDVN
7
DELISTED
MEDIVATION, INC.
MDVN
$138M 4.47%
2,769,412
-90,000
-3% -$4.68M
ALXN
8
DELISTED
Alexion Pharmaceuticals
ALXN
$124M 4.03%
672,428
-55,000
-8% -$10.2M
RDUS
9
DELISTED
Radius Health, Inc.
RDUS
$107M 3.47%
2,752,140
+7,100
+0.3% +$168K
GEVA
10
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
$105M 3.4%
1,130,476
+37,000
+3% +$2.92M
PBYI icon
11
Puma Biotechnology
PBYI
$454M
$98.8M 3.2%
521,991
+45,000
+9% +$9.98M
PCYC
12
DELISTED
PHARMACYCLICS INC
PCYC
$89.4M 2.9%
731,542
– –
REGN icon
13
Regeneron Pharmaceuticals
REGN
$80.8B
$81.2M 2.63%
198,000
-35,000
-15% -$13.8M
RCPT
14
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
$79.8M 2.58%
651,181
+14,408
+2% +$1.46M
ALNY icon
15
Alnylam Pharmaceuticals
ALNY
$29.3B
$72.9M 2.36%
751,288
-30,000
-4% -$2.78M
NBIX icon
16
Neurocrine Biosciences
NBIX
$16.6B
$69M 2.23%
3,086,552
-30,000
-1% -$568K
HALO icon
17
Halozyme
HALO
$12.2B
$65.9M 2.13%
6,825,532
+395,000
+6% +$3.51M
PTCT icon
18
PTC Therapeutics
PTCT
$6.12B
$63.6M 2.06%
+1,227,912
New +$54.1M
TTPH
19
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$51.7M 1.67%
+65,106
New +$35M
NVAX icon
20
Novavax
NVAX
$1.31B
$46.8M 1.52%
395,000
+20,000
+5% +$2.09M
INFI
21
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$39.2M 1.27%
2,320,737
– –
CLVS
22
DELISTED
Clovis Oncology, Inc.
CLVS
$34.6M 1.12%
618,188
+60,000
+11% +$3.15M
TSRO
23
DELISTED
TESARO, Inc.
TSRO
$26.2M 0.85%
704,582
– –
IMGN
24
DELISTED
Immunogen Inc
IMGN
$19.8M 0.64%
3,240,816
+75,000
+2% +$686K
CEMP
25
DELISTED
Cempra, Inc.
CEMP
$18.2M 0.59%
+775,000
New +$11.6M
1
2

Similar funds

SBAM
Santa Barbara Asset Management Los Angeles, California $6.43B AUM 10.99% 1-Year Est. Return
HFS
HL Financial Services Louisville, Kentucky $6.5B AUM 10.02% 1-Year Est. Return
SA
SQ Advisors Naples, Florida $1.32B AUM 10.3% 1-Year Est. Return
WF
WealthTrust Fairport Cleveland, Ohio $1.06B AUM 3.47% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
AB
AT Bancorp Dubuque, Iowa $823M AUM 17.19% 1-Year Est. Return
MFBTD
MB Financial Bank - Trust Department Rosemont, Illinois $816M AUM 5.49% 1-Year Est. Return

BB Biotech's Q4 2014 Portfolio in Review

As of Q4 2014, BB Biotech held 29 positions worth $3.09B, up 26% from $2.46B the previous quarter. Its ten largest holdings account for 71% of the portfolio.

BB Biotech's Q4 2014 filing shows 3 new, 10 increased, 10 reduced and 1 closed positions. Its largest new stake was PTC Therapeutics: 1,227,912 shares worth $63.6M. The largest sale was Ionis Pharmaceuticals, an estimated $32.6M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 84% a quarter earlier.

  • BB Biotech's largest Q4 2014 buy was PTC Therapeutics: 1,227,912 shares worth $63.6M.
  • BB Biotech added most to Gilead Sciences in Q4 2014, an estimated $15.5M increase.
  • BB Biotech's biggest Q4 2014 reduction was Ionis Pharmaceuticals, cutting an estimated $32.6M.
  • BB Biotech fully exited Endocyte, Inc. Common Stock in Q4 2014, selling an estimated $4.16M.
  • BB Biotech's ten largest holdings make up 71% of its $3.09B portfolio in Q4 2014.
  • BB Biotech opened 3 new positions and closed 1 in Q4 2014.
  • BB Biotech's portfolio value rose 26% quarter-over-quarter to $3.09B.

Based on BB Biotech's 13F filing for Q4 2014, filed 12 Feb 2015.